Explore 3 Stock Ideas & Industry Insights Download Free Report

XOMA Royalty Corporation

Company price
None USD 0.00(0%)
Last update at 2026-11-17T21:12:15.387314Z
Market Cap
710.16M
P/E
25.59

Momentum Score

…

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
22.29
Low
45.22
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for XOMA Royalty Corporation (NASDAQ: XOMA) are limited, so its portfolio and strategy are not well documented. If it operates as a royalty holder, growth could come from recurring royalty cash flows and selective acquisitions, which may appeal to investors seeking income-like exposure without operating a drug business.
Key risks include concentration in a small number of royalty assets tied to clinical and regulatory outcomes, counterparty and credit risk on royalty streams, and limited market liquidity or reporting that can make valuation and monitoring difficult.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
48.55M
Revenue Per Share
4.03
Gross Profit TTM
48.09M
Debt / Equity
1.27
ROE
34.23%
Net Debt
48.65M
ROCE
18.85%
Diluted EPS TTM
1.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 31.82M -19.48M -40.83M -17.12M 15.89M
Net income 31.71M -13.82M -40.83M -17.10M 15.80M
Selling general administrative 36.09M 34.48M 25.61M 23.19M 20.46M
Selling and marketing expenses - - 1.57M - -
Gross profit 49.18M 28.28M 4.62M 5.93M 38.16M
Reconciled depreciation 2.97M 0.22M 0.77M 0.10M 0.01M
Ebit 44.85M -5.64M -23.46M -17.41M 17.53M
Ebitda 47.82M -5.42M -22.56M -17.02M 16.65M
Depreciation and amortization 2.97M 0.22M 0.90M 0.40M -0.88M
Non operating income net other - - - 0.29M -1.18M
Operating income 11.38M -39.98M -41.85M -17.41M 17.53M
Other operating expenses 40.77M 68.46M 46.61M 23.44M 20.63M
Interest expense 13.03M 13.84M 0.57M -0.29M 0.46M
Tax provision 0.10M -5.66M 0.00M -0.01M 0.09M
Net interest income -13.03M -13.84M -0.57M 0.00M -0.46M
Income tax expense 0.10M -5.66M 0.73M -0.01M 0.09M
Total revenue 52.15M 28.49M 4.76M 6.03M 38.16M
Total operating expenses 37.79M 68.26M 46.46M 23.44M 20.63M
Cost of revenue 2.96M 0.21M 0.14M 0.10M -
Total other income expense net 20.43M 20.50M 1.02M 0.29M -1.64M
Net income from continuing ops 31.71M -13.82M -26.70M -17.10M 15.80M
Net income applicable to common shares - - - -22.58M 7.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 272.70M 221.28M 234.30M 140.38M 166.56M
Intangible assets 44.76M 25.91M - 15.15M -
Other current assets 29.45M 3.41M 0.48M 0.72M 0.61M
Total liab 168.74M 139.36M 145.58M 16.37M 24.69M
Total stockholder equity 103.96M 81.92M 88.72M 124.01M 141.88M
Other current liab 16.35M 9.84M 11.14M 4.36M 10.06M
Common stock 0.09M 0.09M 0.09M 0.09M 0.09M
Capital stock 0.14M 0.14M 0.14M 0.14M 0.13M
Retained earnings -1221.45M -1237.06M -1223.22M -1182.39M -1165.29M
Other liab - - - 9.55M 11.69M
Other assets - - - 63.94M 69.38M
Cash 82.91M 101.65M 153.45M 57.83M 93.33M
Total current liabilities 34.82M 24.37M 19.50M 6.82M 12.97M
Current deferred revenue 1.27M 1.36M 2.11M 1.90M 1.64M
Net debt 48.65M 17.54M -29.00M -57.79M -93.10M
Short term debt 14.99M 11.84M 5.60M 0.03M 0.20M
Short long term debt 12.53M 11.39M 5.54M - -
Short long term debt total 131.56M 119.20M 124.45M 0.03M 0.23M
Other stockholder equity 1305.20M 1318.77M 1313.18M 1306.27M 1307.03M
Property plant equipment - - - 0.01M 0.01M
Total current assets 117.26M 125.60M 169.31M 61.25M 96.97M
Long term investments - - - - 0.00M
Net tangible assets - - - 108.81M 141.83M
Short term investments 0.38M 3.53M 0.16M 0.34M 0.77M
Net receivables 4.90M 17.02M 15.22M 2.37M 0.21M
Long term debt 96.45M 106.88M 118.52M - -
Inventory - - 0.00M - 2.05M
Accounts payable 2.21M 1.05M 0.65M 0.52M 1.07M
Accumulated other comprehensive income 0.05M 0.07M -1.37M - -
Common stock total equity - - - 0.09M 0.09M
Preferred stock total equity - - - 0.05M 0.05M
Retained earnings total equity - - - -1182.39M -1165.29M
Non currrent assets other 4.03M 5.08M 0.53M 63.94M 69.38M
Non current assets total 155.44M 95.67M 64.99M 79.13M 69.59M
Capital lease obligations 22.58M 0.93M 0.39M 0.03M 0.23M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 6.90M -28.26M -21.47M -20.22M -26.50M
Change to liabilities - - - -0.12M -0.81M
Total cashflows from investing activities 50.89M -28.26M - -20.22M -26.50M
Net borrowings -10.60M -6.90M - - -21.35M
Total cash from financing activities -26.46M -11.13M 120.59M -4.45M 12.84M
Change to operating activities - - - -0.27M -1.68M
Net income 31.71M -13.82M -40.83M -17.10M 15.80M
Change in cash 27.29M -53.13M 95.62M -37.55M 9.01M
Begin period cash flow 106.42M 159.55M 57.83M 95.38M 86.36M
End period cash flow 133.71M 106.42M 153.45M 57.83M 95.38M
Total cash from operating activities 2.87M -13.75M -18.16M -12.88M 22.68M
Issuance of capital stock 4.34M 0.00M - -0.02M 40.00M
Depreciation 2.97M 0.22M 0.90M 0.10M 0.01M
Other cashflows from investing activities 47.13M -23.75M - -4.97M -26.50M
Dividends paid 5.47M 5.47M 5.47M 5.47M 3.50M
Change to inventory - - -0.00M - -0.06M
Change to account receivables -2.43M -0.83M -1.00M 0.21M 0.05M
Sale purchase of stock -16.04M -0.01M -0.15M 2.42M -40.00M
Other cashflows from financing activities -3.07M 1.26M -0.15M 1.02M 20.58M
Change to netincome - - - 3.61M 6.50M
Capital expenditures 20.73M 0.02M 14.67M 23.25M 26.50M
Change receivables - - - 0.21M 0.05M
Cash flows other operating - - - 0.43M 0.94M
Cash and cash equivalents changes - - - -37.55M 9.01M
Change in working capital -11.37M -2.79M -3.53M -0.18M -0.89M
Stock based compensation 9.27M 10.31M 9.10M 3.61M 6.20M
Other non cash items -29.82M -2.01M 15.68M 0.69M 0.26M
Free cash flow 2.87M -13.77M -32.83M -36.13M -3.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

XOMA Royalty Corporation

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

2200 Powell Street, EmeryVille, CA, United States, 94608

510 204 7200

14

Name Title Year Born
Mr. James R. Neal M.B.A., M.S. CEO & Chairman 1956
Mr. Thomas M. Burns Sr. VP of Fin. & CFO 1974
Mr. Owen P. Hughes Jr. CEO & Director 1975
Mr. Thomas M. Burns Senior VP of Finance & CFO 1974
Mr. Brad Sitko Chief Investment Officer 1981
Mr. Bradley Sitko Chief Investment Officer 1981
Mr. Jeffrey Trigilio Chief Financial Officer 1984
Juliane Snowden Head of Investor Relations NA
Ms. Maricel Perea Montano Chief Legal Officer & Corporate Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…